PARP inhibitors, such as olaparib, inhibit homologous recombination during the repair process after DNA damage and thus, exert their antitumor effects by inducing the apoptosis of tumor cells harboring germline BRCA1/2 mutations. The gene discussed is BRCA1; the disease is neoplasm.